Journal Home
Search for

Articles in Press

Return to articles in press list

Meth/amphetamine use and associated HIV: Implications for global policy and public health

Louisa Degenhardt1Corresponding Author Informationemail address, Bradley Mathers2, Mauro Guarinieri3, Samiran Panda4, Benjamin Phillips5, Steffanie A. Strathdee6, Mark Tyndall7, Lucas Wiessing8, Alex Wodak9, John Howard10, the Reference Group to the United Nations on HIV and injecting drug use

Received 29 May 2009; received in revised form 30 October 2009; accepted 24 November 2009. published online 01 February 2010.
Corrected Proof

Abstract 

Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are understandable concerns over potential harms including the transmission of HIV. However, there have been no previous global reviews of the extent to which these drugs are injected or levels of HIV among users. A comprehensive search of the international peer-reviewed and grey literature was undertaken. Multiple electronic databases were searched and documents and datasets were provided by UN agencies and key experts from around the world in response to requests for information on the epidemiology of use. Amphetamine or methamphetamine (meth/amphetamine, M/A) use was documented in 110 countries, and injection in 60 of those. Use may be more prevalent in East and South East Asia, North America, South Africa, New Zealand, Australia and a number of European countries. In countries where the crystalline form is available, evidence suggests users are more likely to smoke or inject the drug; in such countries, higher levels of dependence may be occurring. Equivocal evidence exists as to whether people who inject M/A are at differing risk of HIV infection than other drug injectors; few countries document HIV prevalence/incidence among M/A injectors. High risk sexual behaviour among M/A users may contribute to increased risk of HIV infection, but available evidence is not sufficient to determine if the association is causal. A range of possible responses to M/A use and harm are discussed, ranging from supply and precursor control, to demand and harm reduction. Evidence suggests that complex issues surround M/A, requiring novel and sophisticated approaches, which have not yet been met with sufficient investment of time or resources to address them. Significant levels of M/A in many countries require a response to reduce harms that in many cases remain poorly understood. More active models of engagement with M/A users and provision of services that meet their specific needs are required.

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia

Corresponding Author InformationCorresponding author. Tel.: +61 2 9385 0230; fax: +61 2 9385 0222.

1 Secretariat of the Reference Group to the United Nations on HIV and injecting drug use; Professor of Epidemiology; and Assistant Director.

2 Secretariat of the Reference Group to the United Nations on HIV and injecting drug use.

3 Civil Society Officer, Asia Unit, The Global Fund to Fight AIDS, Tuberculosis and Malaria.

4 Deputy Director, Epidemiology, National Institute of Cholera and Enteric Diseases (Indian Council of Medical Research) and Society for Positive Atmosphere and Related Support to HIV/AIDS (SPARSHA), India.

5 Researcher Officer, National Drug and Alcohol Research Centre, University of New South Wales, Australia.

6 Professor and Harold Simon Chair Chief, Division of International Health and Cross-Cultural Medicine, University of California San Diego, United States.

7 Program Director, Epidemiology, British Columbia Centre for Excellence in HIV/AIDS, Canada.

8 Principal Scientist Infectious Diseases Epidemiology, Crime and markets unit, European Monitoring Centre for Drugs and Drug Addiction, Portugal.

9 Director, Alcohol and Drug Service, St Vincent's Hospital, Sydney, Australia.

10 Senior Lecturer, National Drug and Alcohol Research Centre, University of New South Wales, Australia.

PII: S0955-3959(09)00159-5

doi:10.1016/j.drugpo.2009.11.007